News about "ONO Pharmaceutical "

Mediar Therapeutics, Ono Pharma Enter Collaboration to Develop Novel Fibrosis Therapies

Mediar Therapeutics, Ono Pharma Enter Collaboration to Develop Novel Fibrosis Therapies

Mediar Therapeutics and Ono Pharmaceutical have entered a collaboration and option agreement to discover novel therapies targeting fibro-inflammatory diseases, while Mediar advances its pipeline of fibrosis-focused antibody programmes.

Ono Pharmaceutical | 10/08/2026 | By News Bureau

Ono Pharma Seeks Expanded OPDIVO Use for Anaplastic Thyroid Cancer in Japan

Ono Pharma Seeks Expanded OPDIVO Use for Anaplastic Thyroid Cancer in Japan

Ono Pharma seeks expanded approval for OPDIVO in Japan for unresectable anaplastic thyroid cancer after a trial with Lenvima met its primary endpoint.

Ono Pharmaceutical | 12/06/2026 | By News Bureau 110

Ono Pharmaceutical Partners with Congruence Therapeutics for Neurology and Immunology Drug Discovery

Ono Pharmaceutical Partners with Congruence Therapeutics for Neurology and Immunology Drug Discovery

Ono Pharmaceutical has expanded its collaboration with Congruence Therapeutics, leveraging the Revenir platform to discover small molecule modulators in neurology and immunology. Ono will hold exclusive worldwide option rights for development and commercialisation of resulting candidates.

Ono Pharmaceutical | 03/03/2026 | By Akanki 189

Ono Pharmaceutical Enters into Definitive Agreement with Seikagaku for Co-development and Marketing Collaboration on Gel-One in Japan

Ono Pharmaceutical Enters into Definitive Agreement with Seikagaku for Co-development and Marketing Collaboration on Gel-One in Japan

Ono Pharmaceutical has signed a definitive agreement with Seikagaku Corporation for the co-development and exclusive marketing of Gel-One for osteoarthritis treatment in Japan.

Ono Pharmaceutical | 11/08/2025 | By Mrinmoy Dey 390

Ono and Congruence to Generate Novel Small Molecule Correctors in Oncology Area

Ono and Congruence to Generate Novel Small Molecule Correctors in Oncology Area

Under the terms of the agreement, Congruence will generate small molecule correctors by leveraging Congruence's proprietary drug discovery engine called, Revenir™.

Ono Pharmaceutical | 07/12/2024 | By Aishwarya 519

Ono Announces Acquisition of Deciphera Pharmaceuticals

Ono Announces Acquisition of Deciphera Pharmaceuticals

Ono Pharmaceutical, Co., Ltd. has completed the tender offer to acquire all outstanding shares of common stock of a US biopharmaceutical company, Deciphera Pharmaceuticals, Inc. for USD 25.60 per share (total amount of approximately USD 2.4 billion) net to the seller in cash.

Ono Pharmaceutical | 14/06/2024 | By Aishwarya 836

ONO to Acquire Deciphera Pharma for USD 2.4 Billion

ONO to Acquire Deciphera Pharma for USD 2.4 Billion

Deciphera Pharmaceuticals, Inc. has signed a definitive merger agreement with ONO Pharmaceutical Co., Ltd. (ONO).

ONO Pharmaceutical | 30/04/2024 | By Aishwarya 1639


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members